Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34552875

about

Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors Local ablation for hepatocellular carcinoma in taiwan Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts Management of "very early" hepatocellular carcinoma on cirrhotic patients Treatment of hepatocellular carcinoma: Steps forward but still a long way to go Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.Growth Arrest Specific 1 (Gas1) Gene Overexpression in Liver Reduces the In Vivo Progression of Murine Hepatocellular Carcinoma and Partially Restores Gene Expression Levels Cancer and liver cirrhosis: implications on prognosis and management Minimally invasive image-guided therapies for hepatocellular carcinoma 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma.Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.Percutaneous ablation for small hepatocellular carcinoma.Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma.Laser ablation for small hepatocellular carcinoma.Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma.Influence of ablative margin on local tumor progression and survival in patients with HCC ≤4 cm after laser ablation.Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture.Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.New progress of non-surgical treatments for hepatocellular carcinoma.The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma.Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm.Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience Presentation and outcomes of hepatocellular carcinoma patients at a western centre.Grading of small hepatocellular carcinomas (≤2 cm): correlation between histology, T2 and diffusion-weighted imaging NCCN clinical practice guidelines in oncology: hepatobiliary cancers Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.Hepatocellular carcinoma: natural history, current management, and emerging tools.Optimizing management strategies in special patient populations.Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.

P2860

Q24630594-E09048A4-FE31-40DB-8423-1A2CACD881C5 Q26829892-F783897E-8C98-4CFF-A579-674E6F0F23FD Q26863654-8FDF2920-B10B-4D4C-909A-948760F7ADF0 Q26864406-4F185111-83BB-4BFA-8745-B1C0F40CD018 Q26865456-06DA8432-EAC8-42F1-9ACF-AE308F9359F4 Q27016138-D28FED98-F613-4F2D-916F-754E5D2C9E5B Q27302934-B00C3A82-16BC-4C33-9C3D-C261AB1FB6A1 Q28068579-076BEDB4-8259-4500-92A9-8D72FF194E4C Q28079027-54DEA38E-8E8F-4CE7-BE6F-74D2A763B6F7 Q28392783-25E0E12D-357D-4667-9877-8B199916D829 Q28394414-F3EA9AC4-5042-4EE9-AF95-AE8BEDCEBE3E Q30460837-13B21706-F59C-4F83-9922-E53CB0214BF2 Q30512830-BBE420F3-75A3-4303-B97E-D1F02B2C6B4A Q33427579-6E4AB444-A330-4D6E-85EA-FCC317060C7F Q34098980-8A12C44C-AF8A-4D04-88BD-2217E14DEB2F Q34108430-BA34F781-664C-4D84-8898-A461835D5302 Q34113019-BC25A40E-5D68-4859-B12D-81E93A4928E9 Q34185536-5302E816-8616-43F2-87FB-CE3A60454E19 Q34385204-0E63499B-741F-4453-B7BB-BB5C60864AE8 Q34483032-2062C038-EFB9-4698-BC73-186120099647 Q34647076-96E1CB84-33CE-4D8E-9B1B-681E52ACEEFB Q34826535-A78B3A0E-4AE3-410E-8D42-8C0FCDDAE2DD Q34905429-149838B8-C788-4677-B52E-9B0D003CB239 Q34982068-18A20E26-16DC-45EF-97C2-0B971A27FCD9 Q35037545-428E1D66-C8FD-4C0A-8B47-9425947CA6D7 Q35047457-4C68F40B-20D6-44B7-99F9-738222C23B42 Q35051942-A3B4BC8D-8846-4ACB-B818-CF49CDABA784 Q35122619-A24399B7-6429-4E8C-9535-73EA0B74CF30 Q35154103-0755B29D-BE9E-4845-8B21-C6A125E3A957 Q35166558-E8926625-7C1A-4696-9ED7-5B33B0D3455B Q35171592-F660E07E-D2A2-489F-AF31-F6DAA501AEF4 Q35469004-2E41B5DB-60EE-4F4F-A9D6-C6AD95B77714 Q35535968-8CE15361-D08D-426E-9DB5-77B0318ADD8B Q35676681-44138356-8680-45E2-9774-23C152F93AD9 Q35703937-D93200E1-9515-4237-8C27-CE51A39C6CEF Q36062588-C150B9D3-06CB-4C87-AA50-FDF8864968B1 Q36171275-294B3B4E-B05F-4DC7-B5D1-57E88028F0C9 Q36382644-F184F244-4FD6-44BF-B891-49E58BB84678 Q36476765-7F64E83C-5326-4B42-AA21-59B5A915BB71 Q36610478-52BAD354-352E-4076-B2EF-708E39A3E76A

P2860

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34552875

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Initial response to percutaneo ...... with hepatocellular carcinoma.

@ast

Initial response to percutaneo ...... with hepatocellular carcinoma.

@en

Initial response to percutaneo ...... with hepatocellular carcinoma.

@nl

type

label

Initial response to percutaneo ...... with hepatocellular carcinoma.

@ast

Initial response to percutaneo ...... with hepatocellular carcinoma.

@en

Initial response to percutaneo ...... with hepatocellular carcinoma.

@nl

prefLabel

Initial response to percutaneo ...... with hepatocellular carcinoma.

@ast

Initial response to percutaneo ...... with hepatocellular carcinoma.

@en

Initial response to percutaneo ...... with hepatocellular carcinoma.

@nl

P1433

Q34552875-F50618F8-96D8-47D3-98D2-486C33FD8784

P1476

Q34552875-5972C455-8E19-48DE-B292-CB7D7C3D175F

P2093

Q34552875-3BFD78DA-FE83-490A-892B-C5E3120A1C11

Q34552875-7D573567-E106-4B74-9439-14501F9E04D0

Q34552875-C557E0D2-9BC6-4922-9F16-D088D22E26EC

Q34552875-D3363801-F374-438D-BF1B-7271EE9BE15A

Q34552875-F04D1B17-264C-48D3-A9E8-E7F3EB6A3AE5

Q34552875-F882EE96-EB16-4CFD-A8D3-9BFA85203ACC

P2860

Q34552875-0B8767F2-A924-494B-9D4B-07C99E9F5326

Q34552875-1058081C-3961-499D-BD40-8790140B0E51

Q34552875-1EDB42DB-586C-4461-A633-33224EF1D2A4

Q34552875-21E10CA4-AC5D-4764-A568-EF5B17CBDCBE

Q34552875-2ABA0959-1E9D-4196-B608-61E8D1F9261B

Q34552875-3428FE76-4E4B-409F-8E2B-7D44919DCA4F

Q34552875-3B6DA311-BF4C-4B98-B751-61258E8A2709

Q34552875-430ACAF5-B914-4512-84A2-42A151E95973

Q34552875-4C4C05E6-E8AD-427E-B098-B9B51E11D762

Q34552875-56DE6700-FB73-4906-B22A-DC8DDF733354

P304

Q34552875-7A4733D1-33AA-47A7-ABFF-3038816C2B9D

P31

Q34552875-A9C7DF83-8E8F-418E-8225-DCE56B5CDCE3

P356

Q34552875-BAEE8472-2A67-4BC2-8941-01D7F43C2503

P407

Q34552875-A8FD78BB-CDCC-4C62-BA68-FF4491A81C80

P433

Q34552875-61DECBDC-89F4-40C0-A0B4-916409DF297C

P478

Q34552875-A65A2413-AE04-4810-B6FE-2021D7988161

P50

Q34552875-1F4FA2DE-57E6-47D7-8E0B-96A4C0E94A0D

Q34552875-8213ACC7-43D3-43B0-8AB4-65D9C0D74C3F

Q34552875-B1966AAF-D965-4B8E-98C0-D2F112E4F237

P577

Q34552875-C867A3CC-2CC9-45E7-8C5C-34114FE52063

P5875

Q34552875-87F2AA26-400C-4771-ADD9-3040BB0C2C62

P698

Q34552875-66780922-CA18-4274-9F36-5C83945D4501

P921

Q34552875-7F1EF748-446E-4FBC-AB1E-7E2AE2924532

P356

P1433

P1476

Initial response to percutaneo ...... with hepatocellular carcinoma

@en

P2093

Barcelona Clínic Liver Cancer Group

http://www.w3.org/2001/XMLSchema#string

Concepció Brú

http://www.w3.org/2001/XMLSchema#string

Lluís Bianchi

http://www.w3.org/2001/XMLSchema#string

Manel Solé

http://www.w3.org/2001/XMLSchema#string

Margarita Sala

http://www.w3.org/2001/XMLSchema#string

Ramon Vilana

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatocellular carcinoma

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection.

An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.

Estimating the world cancer burden: Globocan 2000.

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

P304

1352-1360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.20465

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Josep M. Llovet

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8161072

http://www.w3.org/2001/XMLSchema#string

P698

15565564

http://www.w3.org/2001/XMLSchema#string

P921